RESUMO
Lung cancer is one of the most common forms of cancer and accounts for a significant proportion of all cancerrelated deaths. Lung adenocarcinoma (LUAD) accounts for approximately 40% of all cases of lung cancer. In recent years, new developments in both the diagnosis and treatment of LUAD have been achieved. Unfortunately, the prognosis remains poor for patients with malignant LUAD. Hypoxia is a common characteristic of solid tumors and induce the immune evasion by increasing the expression of programmed cell deathligand1 (PDL1) in the tumor. In this study, it was predicted that ubiquitinspecific peptidase 22 (USP22) is the direct target of the microRNA (miR)305p family, including miR30a5p, miR30b5p, miR30c5p, miR30d5p and miR30e5p. Furthermore, the binding of USP22 with the miR305p family was confirmed by luciferase assay. In addition, it was demonstrated that targeting USP22 via the miR305p family inhibited the induction of PDL1 expression in hypoxic conditions, thus preventing activated T cells from killing LUAD cells. Our results indicated that miR30a5p, miR30b5p, miR30c5p, miR30d5p and miR30e5p represent new targets for the treatment of LUAD.